Abstract:Identifying genes that are crucial for cancer cell survival but dispensable in normal cells holds immense therapeutic potential. The DepMap Consortium’s extensive datasets have paved the way for uncovering such selectively essential genes in cancer. However, it remained challenging to efficiently prioritize understudied, selectively essential genes for validation and characterization. To this end, our lab has previously ranked and prioritized potentially understudied, selectively essential genes based on their PubMed publication numbers. This approach led to successful identification and detailed characterization of two top understudied genes. Building on this methodology, our current research identified UXS1, an enzyme responsible for catalyzing the conversion from UDP-glucuronic acid (UDP-GlcA) to UDP-xylose, as a selectively essential gene in cancer cells expressing elevated levels of UGDH, an enzyme responsible for producing UDP-GlcA. Through an integrated approach combining genetic and biochemical assays, we discovered that UXS1 plays a critical role in these UGDH-overexpressing cancer cells by preventing the harmful buildup of UDP-GlcA, which otherwise would lead to cellular toxicity. Our findings not only validate our strategy for prioritizing underexplored but potentially pivotal selectively essential genes but also highlight UXS1 as a potential vulnerability and therapeutic target in cancers characterized by high UGDH expression.

What problem does this paper attempt to address?

This paper aims to explore the mechanism of action of a gene named UXS1 (UDP - glucuronic acid decarboxylase 1) in certain specific cancer cells, especially those cancer cells with high expression of UGDH (UDP - glucose 6 - dehydrogenase). By analyzing the large - scale CRISPR/Cas9 screening data in the DepMap database, the researchers found that UXS1 has selective survival importance in cancer cells with high expression of UGDH, but is not essential in normal cells or most other types of cancer cells. This indicates that UXS1 may become a potential therapeutic target for this type of cancer. Specifically, the problems that the paper attempts to solve are: 1. **Determine in which cancer cells UXS1 is selectively essential**: By analyzing the DepMap data set, the researchers found that UXS1 shows selective dependence in cancer cells with high expression of UGDH, that is, these cells are very sensitive to the deletion of UXS1, while other cells are not affected. 2. **Explain the mechanism of UXS1's selective essentiality**: The researchers proposed two hypotheses: - Hypothesis 1: Cells with high expression of UGDH need more UDP - xylose or its downstream products to support growth. However, the experimental results do not support this hypothesis because knocking out UGDH does not affect the growth of these cells. - Hypothesis 2: The deletion of UXS1 will lead to the accumulation of UDP - glucuronic acid (UDP - GlcA) in cells, thereby causing cytotoxicity. The experimental results support this hypothesis. Knocking out UGDH can protect cells from the growth inhibition caused by the deletion of UXS1, indicating that the excessive accumulation of UDP - GlcA is indeed toxic. 3. **Verify the possibility of UXS1 as a potential therapeutic target**: The researchers have confirmed the key role of UXS1 in cancer cells with high expression of UGDH through a variety of experimental methods, including CRISPR/Cas9 knockout, shRNA knockdown, and metabolite level determination, and this role is achieved by preventing the excessive accumulation of UDP - GlcA. In summary, this paper mainly solves the selective essentiality of UXS1 in cancer cells with high expression of UGDH and the underlying molecular mechanism, providing a theoretical basis for further development of treatment methods for this type of cancer.

UXS1 regulates UDP-GlcA levels to support growth of UGDH-high cancer cells

UXS1: a sweet spot for cell death

UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth

UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology

UPP1 Promotes Lung Adenocarcinoma Progression through Epigenetic Regulation of Glycolysis

The Expression Profiles and Deregulation of UDP-Glycosyltransferase (UGT) Genes in Human Cancers and Their Association with Clinical Outcomes

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway

Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation

SOX9-mediated UGT8 expression promotes glycolysis and maintains the malignancy of non-small cell lung cancer

Tmet-35. Upregulation Of The Uridine Salvage Pathway In Mesenchymal Glioblastoma Stem-Like Cells

UDP-glucose dehydrogenase supports autophagy-deficient PDAC growth via increasing hyaluronic acid biosynthesis

Deacetylation of GLUD1 maintains the survival of lung adenocarcinoma cells under glucose starvation by inhibiting autophagic cell death

UDP-6-glucose dehydrogenase in hormonally responsive breast cancers

Integrative Analyses of Pyrimidine Salvage Pathway-Related Genes Revealing the Associations Between UPP1 and Tumor Microenvironment

SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells

Tmet-40. Upregulation Of Uridine Salvage In Mesenchymal Glioblastoma Stem-Like Cells

UDP-glucose Accelerates SNAI1 Mrna Decay and Impairs Lung Cancer Metastasis

UDP-glucose dehydrogenase expression is upregulated following EMT and differentially affects intracellular glycerophosphocholine and acetylaspartate levels in breast mesenchymal cell lines

Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc − for Glutathione Synthesis in Lung Cancer

Cystine Transporter Regulation of Pentose Phosphate Pathway Dependency and Disulfide Stress Exposes a Targetable Metabolic Vulnerability in Cancer